Where does Noxxon Pharma AG rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Noxxon Pharma AG ranks #17,954 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Noxxon Pharma AG hold?

Noxxon Pharma AG holds 16 US utility patents granted between 2015 and 2022, spanning 11 technology areas.

What is Noxxon Pharma AG's Innovation Score?

Noxxon Pharma AG has an Innovation Score of 36.2 out of 100 (top 47% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Noxxon Pharma AG's patent grant rate increasing or decreasing?

Noxxon Pharma AG's recent grant velocity is -77% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Noxxon Pharma AG's patents?

Noxxon Pharma AG's patents average 17.0 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Noxxon Pharma AG patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Noxxon Pharma AG

Q: What technology areas does Noxxon Pharma AG focus on?

Noxxon Pharma AG's top technology area is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media) with 15 patents, ranking #709 of 4,144 assignees active in that subclass. Grants appear in 11 CPC subclasses total.

USPTO PatentsView assignee record - 16 granted patents across 11 technology areas, recorded in grant years 2015–2022. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Noxxon ranks #17,954 of 49,997 tracked US assignees by granted-patent volume, with 16 patents across 11 technology areas.

#17,954
of 49,997 US assignees by volume: Top 47%
by Innovation Score (36.2/100): 17.0
avg claims per patent: -77%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R17954 · Foreign Corporation #17,954 · 16 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 16 grants
MID-PACK #17,954/49,997
PHOTO-FINISH Ningbo Yusing…
CPC-FOCUS C12N · 11 areas
INNOV-THIN 36.2/100
CLAIMS-RICH 17.0 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DROP -77% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Ningbo Yusing Optoelectonic Technology Co., Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Noxxon’s 36.2 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 9.8 pts (27%) Velocity 4.4 pts (12%) Breadth 11.7 pts (32%) Claim depth 10.2 pts (28%)

Qualcomm Incorporated · highest

85
Noxxon Pharma · this assignee

36
3D Lighting… · lowest

7

What this shows Noxxon's Innovation Score is 36.2/100 (top 47% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Noxxon?

Each dot is one of Noxxon’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Noxxon’s own 17.0 claims/patent is ABOVE the 15.0 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Noxxon vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Noxxon's grants concentrate

Noxxon Pharma AG is a focused PatentsView assignee: 11 CPC subclasses with 93.8% of grants classified under C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media). Peak complete grant year is 2015 (3 grants) versus a trough of 1 in 2020. By volume, Noxxon sits between Ningbo Yusing Optoelectonic Technology Co., Ltd. and Nugen Technologies, Inc..

Noxxon's three-year grant acceleration

Noxxon Pharma AG shows 2 grants in 2022–2024 against only 3 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Ningbo Yusing Opt…

16
Nittoku

16
North American Pi…

16
Northrop Grumman…

16
Nsfocus Informati…

16
NSK Americas

16
Nuclera

16
Nugen

16
Noxxon Pharma ◀

16

What this shows Noxxon holds 16 patents at rank #17,936, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Noxxon

By rank, the assignees closest to #17,936 in granted patent volume.

Leaders in C12N (Microorganisms OR Enzymes)

Other assignees with the most granted patents in Noxxon's primary technology class.

Noxxon's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

36 Top 47% higher than 53% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2022

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Noxxon Pharma AG patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	3	18.8%
2016	2	12.5%
2017	3	18.8%
2018	3	18.8%
2019	2	12.5%
2020	1	6.3%
2022	2	12.5%

Which technologies does Noxxon Pharma AG patent most?

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 15

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 13

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 8

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 6

C07K - Peptides 4

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 3

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 2

Y02P - Climate Change Mitigation Technologies IN THE Production OR Processing OF Goods 1

C12Y - Enzymes 1

C12P - Fermentation OR Enzyme-using Processes TO Synthesise A Desired Chemical Compound OR Composition OR TO Separate Optical Isomers From A Racemic Mixture 1

Y02A - Technologies FOR Adaptation TO Climate Change 1

Top 11 of 11 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Noxxon Pharma AG's patent record in context - here's where to go next.

Noxxon Pharma AG's lead technology class is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media), 93.8% of its portfolio - see every assignee active in that class. Explore C12N
Ranked #17,954 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Noxxon Pharma AG against Ningbo Yusing Optoelectonic Technology Co., Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 36.2/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.